These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Optimization of continuous infusion of piperacillin-tazobactam in children with fever and neutropenia. Delvallée M; Mazingue F; Abouchahla W; Delebarre M; Wallet F; Courcol R; Kipnis E; Dessein R Pediatr Infect Dis J; 2013 Sep; 32(9):962-4. PubMed ID: 23629023 [TBL] [Abstract][Full Text] [Related]
9. Targeted benefits of prolonged-infusion piperacillin-tazobactam in an in vitro infection model of Pseudomonas aeruginosa. Zelenitsky S; Nash J; Weber Z; Iacovides H; Ariano R J Chemother; 2016 Oct; 28(5):390-4. PubMed ID: 27077931 [TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial. Bao H; Lv Y; Wang D; Xue J; Yan Z Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):459-466. PubMed ID: 27796647 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Buck C; Bertram N; Ackermann T; Sauerbruch T; Derendorf H; Paar WD Int J Antimicrob Agents; 2005 Jan; 25(1):62-7. PubMed ID: 15620828 [TBL] [Abstract][Full Text] [Related]
12. Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function. Thabit AK; Grupper M; Nicolau DP; Kuti JL J Pharm Pract; 2017 Dec; 30(6):593-599. PubMed ID: 29121839 [TBL] [Abstract][Full Text] [Related]
13. Investigation of the clinical breakpoints of piperacillin-tazobactam against infections caused by Pseudomonas aeruginosa. Yamagishi Y; Terada M; Ohki E; Miura Y; Umemura T; Mikamo H J Infect Chemother; 2012 Feb; 18(1):127-9. PubMed ID: 21814800 [TBL] [Abstract][Full Text] [Related]
14. Impact of the duration of antibiotics on clinical events in patients with Pseudomonas aeruginosa ventilator-associated pneumonia: study protocol for a randomized controlled study. Bouglé A; Foucrier A; Dupont H; Montravers P; Ouattara A; Kalfon P; Squara P; Simon T; Amour J; Trials; 2017 Jan; 18(1):37. PubMed ID: 28114979 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic evaluation of piperacillin-tazobactam. Hayashi Y; Roberts JA; Paterson DL; Lipman J Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):1017-31. PubMed ID: 20636224 [TBL] [Abstract][Full Text] [Related]
16. Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants. Chen Y; Lu J; Dong M; Wu D; Zhu Y; Li Q; Chen C; Li Z Eur J Clin Pharmacol; 2016 Dec; 72(12):1479-1488. PubMed ID: 27644691 [TBL] [Abstract][Full Text] [Related]
17. Piperacillin/tazobactam-heteroresistant Pseudomonas aeruginosa from urinary infection, successfully treated by piperacillin/tazobactam. Pournaras S; Ikonomidis A; Neou E; Kantzanou M; Maniatis AN; Tsakris A J Antimicrob Chemother; 2008 Mar; 61(3):757-8. PubMed ID: 18199562 [No Abstract] [Full Text] [Related]
18. Intravitreal piperacillin/tazobactam in the management of multidrug-resistant Pseudomonas aeruginosa endophthalmitis. Pathengay A; Mathai A; Shah GY; Ambatipudi S J Cataract Refract Surg; 2010 Dec; 36(12):2210-1. PubMed ID: 21111328 [No Abstract] [Full Text] [Related]
19. Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections. Chen R; Qian Q; Sun MR; Qian CY; Zou SL; Wang ML; Wang LY Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):363-72. PubMed ID: 25894901 [TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulation and steady-state pharmacokinetic data from hospitalized patients. Rotschafer JC; Ullman M Ann Pharmacother; 2009 Nov; 43(11):1887-9. PubMed ID: 19809005 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]